经皮冠状动脉介入治疗后患者个体化抗栓治疗
综述评估了慢性冠脉综合征和急性冠脉综合征患者经皮冠状动脉介入治疗后双联抗血小板治疗的最佳疗程与组成,以及P2Y12抑制剂单药、低剂量Xa因子抑制剂联合抗血小板、血小板功能或基因型指导的降/升阶治疗等新策略。当前指南推荐基于缺血和出血风险分层制定疗程与方案,但风险评分、血小板功能检测和基因分型在临床实践中尚未广泛采用,且外部验证结果不一致。
要点
- 双联抗血小板治疗是PCI术后标准,但最佳疗程和组成需个体化。
- P2Y12抑制剂单药、低剂量Xa因子抑制剂联合抗血小板等新策略显示前景。
- 指南推荐风险分层指导疗程,但风险评分、血小板功能检测和基因分型临床应用有限。
核心结论
- 抗栓治疗需结合风险分层与临床判断实现患者个体化。
研究设计与样本
- 综述,批判性评估现有抗栓策略及风险分层方法。
主要发现
- 部分患者可从缩短或延长治疗疗程中获益。
- 评估P2Y12抑制剂单药、低剂量Xa因子抑制剂联合抗血小板、血小板功能或基因型指导的降/升阶治疗等新策略的试验显示有希望的结果。
- 多种风险评分用于确定最佳疗程,但外部验证在校准和区分度上结果不一致,且采用后改善临床结局的证据有限。
- 血小板功能检测和基因分型可提供预后信息,但以其指导治疗策略的试验结果不一。
关键数值与推荐
- 当前指南推荐对治疗疗程和组成进行风险分层。
临床怎么用
- 临床实践中可将不同风险分层方法与临床判断结合使用。
局限性
- 风险评分外部验证结果在校准和区分度上不一致,且改善临床结局的证据有限。
- 血小板功能检测和基因分型指导治疗策略的试验结果不一。
- 风险分层在临床实践中尚未广泛采用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dual antiplatelet therapy has long been the standard of care in preventing coronary and cerebrovascular thrombotic events in patients with chronic coronary syndrome and acute coronary syndrome undergoing percutaneous coronary intervention, but choosing the optimal treatment duration and composition has become a major challenge. Numerous studies have shown that certain patients benefit from either shortened or extended treatment duration. Furthermore, trials evaluating novel antithrombotic strategies, such as P2Y12 inhibitor monotherapy, low-dose factor Xa inhibitors on top of antiplatelet therapy, and platelet function- or genotype-guided (de-)escalation of treatment, have shown promising results. Current guidelines recommend risk stratification for tailoring treatment duration and composition. Although several risk stratification methods evaluating ischaemic and bleeding risk are available to clinicians, such as the use of risk scores, platelet function testing , and genotyping, risk stratification has not been broadly adopted in clinical practice. Multiple risk scores have been developed to determine the optimal treatment duration, but external validation studies have yielded conflicting results in terms of calibration and discrimination and there is limited evidence that their adoption improves clinical outcomes. Likewise, platelet function testing and genotyping can provide useful prognostic insights, but trials evaluating treatment strategies guided by these stratification methods have produced mixed results. This review critically appraises the currently available antithrombotic strategies and provides a viewpoint on the use of different risk stratification methods alongside clinical judgement in current clinical practice.
引用
- van der Sangen NMR, Rozemeijer R, Chan Pin Yin DRPP, et al. Patient-tailored antithrombotic therapy following percutaneous coronary intervention. Eur Heart J. 2021. PMID: 33515031. doi:10.1093/eurheartj/ehaa1097
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。